IFDA Approved Molecules
Dimethyl Fumarate
Mw.: 144.13 g/mol
Anti-inflammatory,
Cytoprotective Effect,
Which both likely involved in its action in multiple sclerosis patients
Tofacitinib Citrate
Mw.: 504.5 g/mol
Antirheumatic,
Disease Modifying,
Janus Kinase Inhibitor
Empagliflozin
Mw.: m450.91 g/mol Antidiabetic agent, Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor
Apixaban
Mw.: 459.50 g/mol
Factor Xa Inhibitor,
Direct Oral Anticoagulant (DOAC)
Exatecan Mesylate
Mw.: 435.4 g/mol
Topoisomerase I Inhibitor,
Anti-tumor
Dalfampridine
Mw.: 94.12 g/mol
Potassium Channel Blocker
Bortezomib
Mw.: 384.24 g/mol
Antineoplastic Agent,
Proteasome Inhibitor
Sorafenib Tosylate
Mw.: 637.03 g/mol
Antineoplastic Agent,
Tyrosine Kinase Inhibitor,
Vascular Endothelial growth Factor (VEGF) Inhibitor
Zoledronic Acid Monohydrate
Mw.: 290.1 g/mol
Bisphosphonate Derivative
Developed Molecules
Sunitinib Malate
Mw.: 532.6 g/mol
Multi-specific Tyrosine Kinase Receptor Inhibitor
Deruxtecan
Mw.: 1034.1 g/mol
Anti-body Drug Conjugate
Oxaliplatin
Mw.: 397.29g/mol
Platinum-based chemotherapeutic class of drugs
Lenalidomide
Mw.: 259.26 g/mol
Antineoplastic Agent,
Angiogenesis Inhibitor
Glatiramer Acetate
Mw.: 623.7 g/mol
Immunomodulator,
Multiple Sclorosis Treatment
Deferasirox
Mw.: 373.4 g/mol
Iron Chelator
Ticagrelor
Mw.: 522.6g/mol
Antiplatelet Medications
Linagliptin
Mw.: 472.5g/mol
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Nilotinib Hydrochloride Monohydrate
Mw.: 584.0 g/mol
Antineoplastic Agent,
BCR-ABL Tyrosine Kinase Inhibitor
Under Development Molecules
Ibrutinib
Mw.: 440.5 g/mol
Tyrosine Kinase Inhibitor
Voriconazol
Mw.: 349.3 g/mol
Antifungal Medication
Abiraterone Acetate
Mw.: 391.5 g/mol
Anti-androgens (anti-testosterone)